Fig. 6: Pharmacokinetics of insulin icodec and major metabolites in human serum samples.
From: Enhanced disulphide bond stability contributes to the once-weekly profile of insulin icodec
a Pharmacokinetic profiles of insulin icodec (light blue circles), insulin icodec B-chain (containing a disulphide bond connecting Cys 7 and Cys 19; dark blue squares), B29 acylated metabolite (purple inverted triangles) and B24–B29 acylated metabolite (brown triangles) at steady state (after the fifth weekly subcutaneous dose) in people with diabetes. Each time point represents a single value obtained from a pooled plasma sample from 12 human subjects. b Possible metabolic pathways leading to formation of the observed metabolites (Supplementary Table 3). The solid lines represent the most likely paths while the dashed lines represent alternative paths to the observed degradation products of insulin icodec. Source data are provided as a Source Data file and in Supplementary Table 4.
